Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 23;50(1):104.
doi: 10.1186/s13052-024-01675-0.

Critical reappraisal of short-acting bronchodilators for pediatric respiratory diseases

Amelia Licari  1   2 , Sara Manti  3 , Francesco Mastellone  4 , Michele Miraglia Del Giudice  5 , Gian Luigi Marseglia  6   7 , Maria Angela Tosca  8 ; Asthma and Personalized Therapies Committee of the Italian Society of Pediatric Allergy & Immunology (SIAIP)
Collaborators, Affiliations
Review

Critical reappraisal of short-acting bronchodilators for pediatric respiratory diseases

Amelia Licari et al. Ital J Pediatr. .

Abstract

Short-acting bronchodilators are a class of medications commonly used to treat asthma, chronic obstructive pulmonary disease, and other respiratory conditions. The use of these medications has evolved over time as we have gained a better understanding of their effectiveness and safety in the pediatric population. This comprehensive review synthesizes the current understanding of short-acting β2-agonists and short-acting anticholinergics in children. It addresses indications, contraindications, safety considerations, and highlights areas where further research is needed to guide the most effective use of short-acting bronchodilators.

Keywords: Asthma; Bronchiolitis; Children; Short-acting bronchodilators; Wheezing.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Zhang D, Zheng J. The Burden of Childhood Asthma by Age Group, 1990–2019: A Systematic Analysis of Global Burden of Disease 2019 Data. Front Pediatr. 2022;10:823399. doi: 10.3389/fped.2022.823399. - DOI - PMC - PubMed
    1. Royal College of Physicians. Why Asthma Still Kills: the National Review of Asthma Deaths (NRAD) confidential enquiry report. 2014. https://www.rcplondon.ac.uk/projects/outputs/why-asthma-still-kills Accessed 11 Jan 2023.
    1. Nwaru BI, Ekström M, Hasvold P, Wiklund F, Telg G, Janson C. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 2020;55(4):1901872. doi: 10.1183/13993003.01872-2019. - DOI - PMC - PubMed
    1. Bateman ED, Price DB, Wang HC, Khattab A, Schonffeldt P, Catanzariti A, et al. Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study. Eur Respir J. 2022;59(5):2101402. doi: 10.1183/13993003.01402-2021. - DOI - PMC - PubMed
    1. Licari A, Brambilla I, Marseglia A, De Filippo M, Paganelli V, Marseglia GL. Difficult vs. Severe Asthma: Definition and Limits of Asthma Control in the Pediatric Population. Front Pediatr. 2018;6:170. 10.3389/fped.2018.00170. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources